Literature DB >> 25840558

Trends in initial management of prostate cancer in New Hampshire.

Johann P Ingimarsson1, Maria O Celaya, Michael Laviolette, Judy R Rees, Elias S Hyams.   

Abstract

PURPOSE: Prostate cancer management strategies are evolving with increased understanding of the disease. Specifically, there is emerging evidence that "low-risk" cancer is best treated with observation, while localized "high-risk" cancer requires aggressive curative therapy. In this study, we evaluated trends in management of prostate cancer in New Hampshire to determine adherence to evidence-based practice.
METHODS: From the New Hampshire State Cancer Registry, cases of clinically localized prostate cancer diagnosed in 2004-2011 were identified and classified according to D'Amico criteria. Initial treatment modality was recorded as surgery, radiation therapy, expectant management, or hormone therapy. Temporal trends were assessed by Chi-square for trend.
RESULTS: Of 6,203 clinically localized prostate cancers meeting inclusion criteria, 34, 30, and 28% were low-, intermediate-, and high-risk disease, respectively. For low-risk disease, use of expectant management (17-42%, p < 0.001) and surgery (29-39%, p < 0.001) increased, while use of radiation therapy decreased (49-19 %, p < 0.001). For intermediate-risk disease, use of surgery increased (24-50%, p < 0.001), while radiation decreased (58-34%, p < 0.001). Hormonal therapy alone was rarely used for low- and intermediate-risk disease. For high-risk patients, surgery increased (38-47%, p = 0.003) and radiation decreased (41-38%, p = 0.026), while hormonal therapy and expectant management remained stable. DISCUSSION: There are encouraging trends in the management of clinically localized prostate cancer in New Hampshire, including less aggressive treatment of low-risk cancer and increasing surgical treatment of high-risk disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25840558     DOI: 10.1007/s10552-015-0574-8

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  11 in total

Review 1.  Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

Authors:  Jeffrey J Tosoian; Stacy Loeb; Jonathan I Epstein; Baris Turkbey; Peter L Choyke; Edward M Schaeffer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

Review 2.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

3.  Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.

Authors:  Sigrid Carlsson; Nicole Benfante; Ricardo Alvim; Daniel D Sjoberg; Andrew Vickers; Victor E Reuter; Samson W Fine; Hebert Alberto Vargas; Michal Wiseman; Maha Mamoor; Behfar Ehdaie; Vincent Laudone; Peter Scardino; James Eastham; Karim Touijer
Journal:  J Urol       Date:  2019-12-23       Impact factor: 7.450

4.  Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.

Authors:  Stacy Loeb; Yasin Folkvaljon; Caitlin Curnyn; David Robinson; Ola Bratt; Pär Stattin
Journal:  JAMA Oncol       Date:  2017-10-01       Impact factor: 31.777

Review 5.  Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.

Authors:  Colton H Walker; Kathryn A Marchetti; Udit Singhal; Todd M Morgan
Journal:  World J Urol       Date:  2021-03-02       Impact factor: 4.226

6.  Invasive Cancer Incidence and Survival - United States, 2013.

Authors:  S Jane Henley; Simple D Singh; Jessica King; Reda J Wilson; Mary Elizabeth O'Neil; A Blythe Ryerson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-01-27       Impact factor: 17.586

7.  Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

Authors:  Julie Y An; Abhinav Sidana; Peter L Choyke; Bradford J. Wood; Peter A Pinto; İsmail Barış Türkbey
Journal:  Balkan Med J       Date:  2017-09-29       Impact factor: 2.021

Review 8.  Entering an era of radiogenomics in prostate cancer risk stratification.

Authors:  Nachiketh Soodana-Prakash; Radka Stoyanova; Abhishek Bhat; Maria C Velasquez; Omer E Kineish; Alan Pollack; Dipen J Parekh; Sanoj Punnen
Journal:  Transl Androl Urol       Date:  2018-09

9.  Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation.

Authors:  Zachary A K Frosch; Nicholas Illenberger; Nandita Mitra; Daniel J Boffa; Matthew A Facktor; Heidi Nelson; Bryan E Palis; Justin E Bekelman; Lawrence N Shulman; Samuel U Takvorian
Journal:  JAMA Netw Open       Date:  2021-07-01

Review 10.  Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review.

Authors:  Koen Degeling; Amanda Pereira-Salgado; Niall M Corcoran; Paul C Boutros; Peter Kuhn; Maarten J IJzerman
Journal:  Eur Urol Open Sci       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.